Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02529553 | A Study of LY3076226 in Participants With Advanced or Metastatic Cancer | PHASE1 | COMPLETED | 25 | — | — | Sep 1, 2015 | Mar 28, 2018 | Apr 17, 2020 | 4 | United States, Canada |
The MTD was defined as the highest dose tested that had less than 33% probability of causing a dose limiting toxicity (DLT).
| Arm | Type | Description |
|---|---|---|
| LY3076226 | EXPERIMENTAL | Part A (dose escalation in advanced cancer): LY3076226 administered intravenously (IV) on day 1 of each 21 day cycle. Part B (dose expansion in advanced urothelial carcinoma): LY3076226 administered IV on day 1 of each 21 day cycle. |
| Name | Type | Description |
|---|---|---|
| LY3076226 | DRUG | Administered IV |
Inclusion Criteria: * Have advanced or metastatic cancer and be an appropriate candidate for experimental therapy. * Part B: Have a diagnosis of bladder cancer. * Part B: Have alterations of FGFR3. * Have adequate organ function. * Have discontinued previous treatments for cancer and have reso...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |